Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline
Overview
The aim of this study is to determine whether common CYP1A2 gene polymorphisms effect metabolism of theophylline in Han and Uygur Patients with chronic obstructive pulmonary disease patients.
Full Title of Study: “Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline in Han and Uygur Patients With COPD”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Other
- Masking: None (Open Label)
- Study Primary Completion Date: June 1, 2017
Interventions
- Drug: Theophylline
- After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it’s metabolites and the genotypes of CYP1A2
Arms, Groups and Cohorts
- Experimental: theophylline
Clinical Trial Outcome Measures
Primary Measures
- Plasma concentrations of theophylline
- Time Frame: one week
- Blood samples will be taken after receiving oral theophylline
Participating in This Clinical Trial
Inclusion Criteria
- Aged 18-75 years,Weight 40-80kg COPD patients, male or female; regularly visiting our hospital; taking a sustained-release preparation of theophylline continuously for at least 2 weeks Exclusion Criteria:
- Patients with renal or hepatic dysfunction; Patients with congestive heart failure; Patients with hypothyroidism or hyperthyroidism; Patients currently taking drugs likely to effect theophylline metabolism or who had taken such drugs in the preceding week; Patients with extreme obesity Patients with very severe Chronic Obstructive Pulmonary Disease(COPD)
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- XiaoGuang Zou
- Collaborator
- Southern Medical University, China
- Provider of Information About this Clinical Study
- Sponsor-Investigator: XiaoGuang Zou, Professor of Pharmacy – Kashgar 1st People’s Hospital
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.